Gatti M.; Raschi E.; Poluzzi E.; Martignani C.; Salvagni S.; Ardizzoni A.; Diemberger I., The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia, «CURRENT HEART FAILURE REPORTS», 2020, 17, pp. 365 - 383 [articolo]Open Access
Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Conci N.; Minari R.; Tiseo M.; Ardizzoni A., The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter, «CLINICAL CANCER RESEARCH», 2020, 26, pp. 518 - 519 [articolo]
Lamberti G.; Sisi M.; Andrini E.; Palladini A.; Giunchi F.; Lollini P.-L.; Ardizzoni A.; Gelsomino F., The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?, «CANCERS», 2020, 12, Article number: 3129, pp. 1 - 21 [articolo]Open Access
Rizzo A.; Mollica V.; Ricci A.D.; Maggio I.; Massucci M.; Rojas Limpe F.L.; Fabio F.D.; Ardizzoni A., Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis, «FUTURE ONCOLOGY», 2020, 16, pp. 4409 - 4418 [articolo]
Livi, Vanina; Ardizzoni, Andrea; Cancellieri, Alessandra; Natali, Filippo; Ferrari, Marco; Paioli, Daniela; De Biase, Dario; Capizzi, Elisa; Tallini, Giovanni; Fiorentino, Michelangelo; Trisolini, Rocco, Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer, «THE CLINICAL RESPIRATORY JOURNAL», 2019, 13, pp. 590 - 597 [articolo]
Rihawi K ; Giannarelli D ; Galetta D ; Delmonte A ; Giavarra M ; Turci D ; Garassino M ; Tiseo M ; Barbieri ; Panni S ; Ardizzoni A;, BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience, «JOURNAL OF THORACIC ONCOLOGY», 2019, 14, pp. 57 - 59 [articolo]
Iacovelli, Roberto; Ciccarese, Chiara; Fornarini, Giuseppe; Massari, Francesco; Bimbatti, Davide; Mosillo, Claudia; Rebuzzi, Sara Elena; Di Nunno, Vincenzo; Grassi, Massimiliano; Fantinel, Emanuela; Ardizzoni, Andrea; Tortora, Giampaolo, Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2019, 85, pp. 1283 - 1289 [articolo]
Nuvola G.; Dall'Olio F.G.; Melotti B.; Sperandi F.; Ardizzoni A., Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect, «JOURNAL OF THORACIC ONCOLOGY», 2019, 14, pp. e145 - e146 [articolo]
Capizzi E.; Dall'Olio F.G.; Gruppioni E.; Sperandi F.; Altimari A.; Giunchi F.; Fiorentino M.; Ardizzoni A., Clinical significance of ROS1 5’ deletions in non-small cell lung cancer, «LUNG CANCER», 2019, 135, pp. 88 - 91 [articolo]
Francesco Gelsomino,Giancarlo Facchini, Maria Aurelia Barbera,
Giuseppe Lamberti, Stefano Brocchi, Giuseppe Rossi,
Andrea Ardizzoni, Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC, «JOURNAL OF THORACIC ONCOLOGY», 2019, 14, pp. 141 - 143 [articolo]
Cho B.C.; Obermannova R.; Bearz A.; McKeage M.; Kim D.-W.; Batra U.; Borra G.; Orlov S.; Kim S.-W.; Geater S.L.; Postmus P.E.; Laurie S.A.; Park K.; Yang C.-T.; Ardizzoni A.; Bettini A.C.; de Castro G.; Kiertsman F.; Chen Z.; Lau Y.Y.; Viraswami-Appanna K.; Passos V.Q.; Dziadziuszko R., Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study, «JOURNAL OF THORACIC ONCOLOGY», 2019, 14, pp. 1255 - 1265 [articolo]
Cinausero M.; Rihawi K.; Cortiula F.; Follador A.; Fasola G.; Ardizzoni A., Emerging therapies in malignant pleural mesothelioma, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2019, 144, Article number: 102815, pp. 1 - 9 [articolo]Open Access
Fumarola C.; Bozza N.; Castelli R.; Ferlenghi F.; Marseglia G.; Lodola A.; Bonelli M.; La Monica S.; Cretella D.; Alfieri R.; Minari R.; Galetti M.; Tiseo M.; Ardizzoni A.; Mor M.; Petronini P.G., Expanding the arsenal of FGFR inhibitors: A novel chloroacetamide derivative as a new irreversible agent with anti-proliferative activity against FGFR1-amplified lung cancer cell lines, «FRONTIERS IN ONCOLOGY», 2019, 9, Article number: 179, pp. 1 - 12 [articolo]Open Access
Urbini, Milena; Indio, Valentina; Tarantino, Giuseppe; Ravegnini, Gloria; Angelini, Sabrina; Nannini, Margherita; Saponara, Maristella; Santini, Donatella; Ceccarelli, Claudio; Fiorentino, Michelangelo; Vincenzi, Bruno; Fumagalli, Elena; Casali, Paolo Giovanni; Grignani, Giovanni; Pession, Andrea; Ardizzoni, Andrea; Astolfi, Annalisa*; Pantaleo, Maria Abbondanza, Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST, «GENES, CHROMOSOMES & CANCER», 2019, 58, pp. 636 - 642 [articolo]Open Access
Pantaleo M.A.; Tarantino G.; Agostinelli C.; Urbini M.; Nannini M.; Saponara M.; Castelli C.; Stacchiotti S.; Fumagalli E.; Gatto L.; Santini D.; De Leo A.; Marafioti T.; Akarca A.; Sabattini E.; pession A.; Ardizzoni A.; Indio V.; Astolfi A., Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response, «ONCOIMMUNOLOGY», 2019, 8, Article number: e1617588, pp. e1617588 - e1617588-10 [articolo]
